These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18821278)

  • 21. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
    Holman AJ; Ng E
    Auton Neurosci; 2008 Dec; 143(1-2):58-67. PubMed ID: 18632310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
    Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
    Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
    [No Abstract]   [Full Text] [Related]  

  • 25. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 26. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
    Frankel EH; Strober BE; Crowley JJ; Fivenson DP; Woolley JM; Yu EB; Xia HA; Chiou CF; Stevens SR
    Cutis; 2007 Apr; 79(4):322-6. PubMed ID: 17500381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriatic arthritis: treatment strategies using biologic agents.
    D'Angelo S; Palazzi C; Olivieri I
    Reumatismo; 2012 Jun; 64(2):113-21. PubMed ID: 22690388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha inhibitors in dermatology.
    Cordoro KM; Feldman SR
    Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments.
    Hick J; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):972-6. PubMed ID: 17884244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey.
    Jani M; Macphie E; Rao C; Moore S; Mirjafari H; McLoughlin Y; Chinoy H; Shah P
    Clin Med (Lond); 2014 Feb; 14(1):95-6. PubMed ID: 24532765
    [No Abstract]   [Full Text] [Related]  

  • 34. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
    Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
    Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
    [No Abstract]   [Full Text] [Related]  

  • 35. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.
    Bojke L; Epstein D; Craig D; Rodgers M; Woolacott N; Yang H; Sculpher M
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv39-iv47. PubMed ID: 21859705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Novel biologics in treatment of psoriatic arthritis].
    ZHOU J; ZHENG M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):404-8. PubMed ID: 19693980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
    Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
    Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.